Compare Amphastar Pharmaceuticals Inc (AMPH) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Consumer Discretionary Select Sector SPDR Fund trades at $116.88. The key difference: Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XLY | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $124.52 |
52-Week Low | $16.87 | $105.64 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
XLY trades at $117.24, up 0.33% today, with neutral technical signals from oscillators and a bearish moving average trend. Support levels are at $115 and $114, while resistance sits near $118. Analyst consensus is unanimously bullish with a 100% buy rating. Recent news highlights consumer discretionary sector strength amid inflation pressures and holiday spending trends.
The outlook for XLY is positive given strong analyst support, though technical indicators show mixed signals with near-term resistance. Risks include consumer sentiment erosion and inflation impacts on discretionary spending. Upside potential hinges on sustained economic growth and sector outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
